DUBLIN--(BUSINESS WIRE)--The "Pigmented Villonodular Synovitis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Pigmented Villonodular Synovitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 3 and 2 respectively.
Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Pigmented Villonodular Synovitis - Overview
- Pigmented Villonodular Synovitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Pigmented Villonodular Synovitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Co
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Plexxikon Inc
For more information about this report visit https://www.researchandmarkets.com/research/nrp7pb/pigmented
